Autoimmune disease questions on Step 1 love to disguise themselves: a patient “just” has anemia, rash, dry mouth, hematuria, or neuropathy—until you zoom out and recognize the immune system is attacking self. This post builds a clean mental model of autoimmune mechanisms (what breaks, why it breaks, and what it looks like clinically), then ties it to the transplant/immunology framework the NBME expects.
The Big Picture: What “Autoimmunity” Actually Means
Autoimmunity = loss of immunologic self-tolerance leading to immune-mediated tissue injury.
Two core requirements:
- Self-reactive lymphocytes exist (they always do—deletion is never 100% complete).
- Regulatory/tolerance checkpoints fail and/or an inflammatory context activates those cells.
High-yield framing:
- Autoimmunity is often a Type II, III, or IV hypersensitivity mechanism.
- Most diseases are multifactorial: genetics (especially HLA) + environment (infection, smoking, UV, drugs) + immune dysregulation.
First Aid cross-ref (Immunology): Hypersensitivity types; Central vs peripheral tolerance; Autoimmune diseases tables (rheum, renal, endocrine).
Self-Tolerance: Where It Breaks (Central vs Peripheral)
Central Tolerance (Primary Lymphoid Organs)
Where:
- T cells in thymus
- B cells in bone marrow
Mechanisms:
- Negative selection deletes strongly self-reactive clones.
- Receptor editing (B cells) can “redo” the BCR to reduce self-reactivity.
Classic Step association: AIRE
- AIRE gene enables thymic medullary cells to express “peripheral” antigens for negative selection.
- Defect → APS-1 (Autoimmune Polyendocrine Syndrome type 1):
- Autoimmune endocrinopathies (hypoparathyroid, adrenal insufficiency)
- Chronic mucocutaneous candidiasis
HY callout: AIRE defect = central tolerance failure.
Peripheral Tolerance (Secondary Lymphoid Organs & Tissues)
Even after central tolerance, autoreactive cells can escape. Peripheral tolerance prevents them from activating.
Key mechanisms:
- Anergy: antigen recognition without costimulation → functional unresponsiveness
- T cells require B7 (CD80/86) on APC binding CD28 on T cell
- Suppression by Tregs: Tregs (FOXP3+) dampen immune responses (IL-10, TGF-β)
- Deletion/apoptosis: activation-induced cell death (e.g., Fas-mediated pathways)
Classic Step associations
- FOXP3 mutation → IPEX
- Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked
- Eczema, watery diarrhea, type 1 diabetes (early onset)
- CTLA-4: inhibitory receptor on T cells that binds B7 to turn off activation
- Blocking CTLA-4 (ipilimumab) can cause immune-related adverse events (colitis, dermatitis, endocrinopathies)
First Aid cross-ref: T cell activation (Signal 1/2), CTLA-4, AIRE, FOXP3; immunotherapy adverse effects.
Why Autoimmunity Happens: The Pathophysiology Themes
1) Molecular Mimicry
Microbial antigens resemble self antigens → cross-reactive immune response.
Classic examples
- Rheumatic fever: anti-strep M protein cross-reacts with heart tissue
- Guillain-Barré: Campylobacter jejuni triggering peripheral nerve damage (often via anti-ganglioside antibodies)
NBME clue: recent infection + new autoimmune symptoms.
2) Bystander Activation / Inflammation-Driven Costimulation
Infection or tissue damage upregulates APC costimulation and cytokines → autoreactive T cells that were previously “quiet” get activated.
3) Epitope Spreading
Initial immune attack exposes additional self-antigens → immune response broadens over time.
Common in chronic autoimmune diseases (e.g., SLE).
4) Release of Sequestered Antigens
Immune-privileged sites (eye, testis, CNS) have antigens normally hidden from immune surveillance.
- Trauma/surgery exposes antigens → autoimmune response
Mechanisms of Tissue Injury: Map Autoimmunity to Hypersensitivity Types
Quick Table: Autoimmune Injury Patterns
| Hypersensitivity | Immune players | Key injury mechanism | Classic autoimmune examples |
|---|---|---|---|
| Type II | IgG/IgM vs cell surface/ECM | Complement, opsonization, ADCC, receptor modulation | Autoimmune hemolytic anemia, ITP, Goodpasture, Graves, Myasthenia gravis |
| Type III | Immune complexes | Deposition → complement → neutrophils | SLE, post-strep GN, serum sickness |
| Type IV | T cells (Th1/Th17, CD8+) | Cytokine-mediated inflammation or direct cytotoxicity | Type 1 DM, MS, Hashimoto, contact dermatitis |
HY pattern recognition
- Type II: “antibody against a specific target” (RBC, platelet, basement membrane, receptor)
- Type III: “systemic symptoms + complement consumption + kidney/joint involvement”
- Type IV: “delayed, T-cell mediated; biopsy shows lymphocytes/macrophages”
First Aid cross-ref: Hypersensitivity table; SLE, Goodpasture, Graves/MG, T1DM.
Clinical Presentation: How Autoimmunity Shows Up on Exams
Autoimmune disease often clusters into recurring presentations:
Systemic inflammatory symptoms
- Fatigue, low-grade fever, weight changes
- Arthralgias/myalgias
Organ-specific red flags
- Skin: malar rash/photosensitivity (SLE), vitiligo, eczema-like rashes
- Joints: symmetric small-joint pain with morning stiffness (RA)
- Kidney: hematuria/proteinuria, edema (SLE nephritis, vasculitis, anti-GBM)
- Neuro: weakness/fatigability (MG), sensory loss/ascending weakness (GBS), optic neuritis (MS)
- Endocrine: hyper/hypothyroid, adrenal insufficiency, type 1 diabetes
- Mucosa: dry eyes/mouth (Sjögren)
“Autoimmune clustering” clue
Multiple autoimmune conditions in the same patient/family, especially with HLA associations.
Diagnosis: What to Order (and How NBME Expects You to Interpret It)
Stepwise approach
- Recognize the pattern (Type II vs III vs IV; systemic vs organ-specific)
- Screen inflammation/organ damage
- CBC (cytopenias), CMP, urinalysis, ESR/CRP
- Use targeted autoantibodies for confirmation
- Confirm tissue injury when needed (biopsy is often definitive)
High-yield labs and concepts
ANA: sensitive, not specific
- ANA is a screening test (often SLE/Sjögren/mixed connective tissue disease).
- If ANA is positive, follow with specific antibodies.
Complement levels
- Low C3/C4 suggests immune complex disease (Type III) like active SLE.
Coombs (Direct Antiglobulin Test)
- Detects antibody/complement on RBC surface → autoimmune hemolysis (Type II).
Biopsy patterns (high-yield)
- Linear IgG along GBM: anti-GBM (Goodpasture)
- Granular (“lumpy-bumpy”): immune complex deposition (SLE, post-strep GN)
Treatment Principles: The Immune System Is a Lever—Know What You’re Pulling
Foundational strategy
- Reduce inflammation (NSAIDs, steroids)
- Suppress immune activation (DMARDs, antimetabolites, calcineurin inhibitors)
- Target key cytokines/cells (biologics)
- Treat complications (organ support, infection prophylaxis)
High-yield immunosuppressants (with Step-style hooks)
| Drug/Class | Mechanism | Common uses in autoimmune/transplant world | Classic toxicities |
|---|---|---|---|
| Glucocorticoids | ↓ NF-κB, ↓ cytokines, ↓ T cell activation | Flares of many autoimmune diseases | Hyperglycemia, osteoporosis, adrenal suppression |
| Methotrexate | Inhibits DHFR; ↑ adenosine (anti-inflammatory) | RA, psoriasis, IBD | Hepatotoxicity, myelosuppression, mucositis; give folate |
| Azathioprine / 6-MP | Purine synthesis inhibition | SLE, IBD, transplant | Myelosuppression; ↑ toxicity with allopurinol |
| Mycophenolate | Inhibits IMP dehydrogenase (↓ guanine) | Lupus nephritis, transplant | GI upset, infections |
| Cyclosporine/Tacrolimus | Calcineurin inhibition → ↓ IL-2 → ↓ T-cell activation | Transplant, some autoimmune | Nephrotoxicity; cyclosporine causes gingival hyperplasia/hirsutism |
| TNF-α inhibitors (infliximab, adalimumab, etanercept) | Block TNF-α | RA, IBD, psoriasis, ankylosing spondylitis | Reactivation TB/fungi; avoid in severe CHF, demyelinating disease |
| Rituximab | Anti-CD20 → B-cell depletion | RA, some vasculitides, refractory autoimmune cytopenias | Infusion reactions, hepatitis B reactivation |
| IVIG / Plasmapheresis | Neutralize/remove pathogenic antibodies | GBS, MG crisis, ITP, some vasculitis | Thrombosis/renal issues (IVIG), line risks (PLEX) |
First Aid cross-ref: Immunosuppressants (transplant section), biologics, cytokine inhibitors, calcineurin inhibitors.
High-Yield Associations You Should Memorize (Autoimmunity + HLA)
HLA associations are exam gold because they connect genetic risk to clinical syndromes.
| HLA | Associated diseases | Hook |
|---|---|---|
| HLA-B27 | Ankylosing spondylitis, reactive arthritis, psoriatic arthritis, IBD-associated arthritis | “Seronegative spondyloarthropathies” |
| HLA-DR3 | Type 1 DM, SLE, Graves, Hashimoto, Addison | Autoimmune endocrine cluster + SLE |
| HLA-DR4 | RA, type 1 DM | RA + T1DM |
| HLA-DQ2/DQ8 | Celiac disease | Gluten-sensitive enteropathy |
Autoimmunity Meets Transplant: The Conceptual Bridge (High-Yield)
Even though “autoimmune disease” and “transplant rejection” are different, Step questions test the shared immunology:
Shared idea: T-cell activation rules everything
- Signal 1: TCR recognizes antigen on MHC
- Signal 2: costimulation (B7–CD28)
- Inhibition: CTLA-4, PD-1 pathways
If you understand why self-reactive T cells activate in autoimmunity, you also understand why alloreactive T cells activate in transplant rejection.
A quick transplant tie-in (because it’s often paired)
- Hyperacute rejection (minutes-hours): preformed anti-ABO/HLA antibodies → thrombosis (Type II-like)
- Acute rejection (days-weeks): T-cell mediated ± antibody; vasculitis
- Chronic rejection (months-years): fibrosis, vascular narrowing
Why it matters for autoimmune mechanisms
- Many treatments overlap (steroids, calcineurin inhibitors, antimetabolites).
- Many complications overlap (opportunistic infections, malignancy risk).
First Aid cross-ref: Transplant rejection types; immunosuppressant mechanisms.
Rapid-Fire “If You See This, Think That” (USMLE Style)
- Low C3/C4 + nephritic/nephrotic signs + multisystem symptoms → immune complex disease (often SLE)
- Linear immunofluorescence + hemoptysis + hematuria → anti-GBM (Goodpasture)
- Fluctuating weakness worse with use, improves with rest → myasthenia gravis (Type II, antibodies against postsynaptic ACh receptor)
- Hyperthyroid symptoms + exophthalmos + pretibial myxedema → Graves (Type II, stimulatory antibodies)
- T1DM child + eczema + severe diarrhea → IPEX (FOXP3)
- Multiple endocrine autoimmunity + chronic mucocutaneous candidiasis → AIRE (APS-1)
- TNF inhibitor patient with cough/weight loss/night sweats → reactivated TB
First Aid “Where to Look” Checklist (Fast Cross-Reference Map)
- Immunology
- Central vs peripheral tolerance (AIRE, FOXP3)
- T-cell activation (B7-CD28; CTLA-4)
- Hypersensitivity types II/III/IV
- Pharmacology
- Immunosuppressants (steroids, calcineurin inhibitors, antimetabolites)
- Biologics (anti-TNF, anti-CD20)
- Systems
- Rheumatology (SLE, RA, vasculitis patterns)
- Endocrine (T1DM, Graves, Hashimoto, Addison)
- Renal (Goodpasture, lupus nephritis patterns)
- Neuro (MG, MS, GBS)
Final Mental Model (What to Hold in Your Head on Test Day)
- Tolerance fails (AIRE/FOXP3/costimulation balance)
- Autoreactive lymphocytes activate (often after infection/inflammation)
- Injury occurs via Type II, III, or IV mechanisms
- Diagnosis = pattern recognition + targeted antibodies + complement/biopsy when needed
- Treatment = steroids for control + DMARD/biologic for long-term suppression + watch infections